TICKERNERD
Menu
LLYLLYHealthcare · Drug Manufacturers - General

LLY Stock Forecast: Eli Lilly & Co. Price Predictions for 2026-2027

Last close, 11 Aug 2026
$1,215
−1.37% on the day

The 28 Wall Street analysts covering Eli Lilly & Co. hold a median 12-month price target of $1,344 — +10.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 10 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.1T
Ticker Nerd rank
90 / 100
Median analyst target
$1,344
Analysts covering
28
Total return, dividends reinvested
1W
+8.9%
1M
+2.2%
YTD
+13.4%
1Y
+92.6%
From 52W high
−1.7%
From 52W low
+92.6%
$631
$1,236
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LLY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Eli Lilly & Co. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
97
Volatility
95
Revisions
92
Growth
87
Momentum
79
Issuance
40
Accruals
22
Size
0

Quality (99): The business earns solid, repeatable profits on what it owns.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Wall Street

LLY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LLY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$600$800$1,000$1,200$1,400$1,600Oct 25Jan 26Apr 26Jul 26LLYHigh $1,600Median $1,344Low $850

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says28 analysts
22 Buy4 Hold2 Sell
Low $850Median $1,344High $1,600

The green dot is the last close — the median target sits +10.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Truist SecuritiesMaintainsBuy$1,370 → $1,376
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$1,350 → $1,410
6 Aug 2026Wells FargoMaintainsOverweight$1,280 → $1,330
15 July 2026CitigroupMaintainsBuy$1,500 → $1,600
15 July 2026CitigroupMaintainsBuy—
14 July 2026BernsteinMaintainsOutperform$1,300 → $1,385
14 July 2026BernsteinMaintainsOutperform—
13 July 2026GuggenheimMaintainsBuy—
13 July 2026GuggenheimMaintainsBuy$1,235 → $1,273
13 July 2026UBSMaintainsBuy—
13 July 2026UBSMaintainsBuy$1,250 → $1,425
10 July 2026B of A SecuritiesMaintainsBuy$1,251 → $1,334
10 July 2026B of A SecuritiesMaintainsBuy—
8 July 2026Morgan StanleyMaintainsOverweight—
8 July 2026Morgan StanleyMaintainsOverweight$1,344 → $1,347
8 July 2026RBC CapitalMaintainsOutperform$1,250 → $1,500
8 July 2026RBC CapitalMaintainsOutperform—
8 July 2026Truist SecuritiesMaintainsBuy$1,281 → $1,370
8 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LLY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LLY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.2%
Analysts raising
1
Analysts cutting
16
Fundamentals

Eli Lilly & Co. (LLY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
41.4×

Cheaper than 19% of US stocks

Price / sales
13.8×

Cheaper than 12% of US stocks

Price / book
35.3×

Cheaper than 3% of US stocks

EV / EBITDA
26.4×

Cheaper than 11% of US stocks

Growth & margins
Revenue growth (YoY)
47.7%

Higher than 85% of US stocks

Earnings growth (YoY)
25.3%

Higher than 64% of US stocks

Gross margin
85.8%

Higher than 94% of US stocks

Operating margin
54.2%

Higher than 98% of US stocks

Net margin
33.5%

Higher than 92% of US stocks

Returns & dividend
Return on equity
102.3%

Higher than 96% of US stocks

Return on assets
20.4%

Higher than 99% of US stocks

Dividend yield
0.6%

Higher than 11% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LLY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
LLYEli Lilly & Co.$1.1T
90
JNJJohnson & Johnson$630.5B
92
ABBVAbbVie, Inc.$438.1B
94
MRKMerck & Co., Inc.$324.9B
55
AMGNAmgen, Inc.$224.9B
92
GILDGilead Sciences, Inc.$165.2B
90
PFEPfizer Inc.$153.8B
71

The rank is the raw material. Whether the rules would actually own Eli Lilly & Co. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LLY news & analysis

Better Buy: Eli Lilly vs. Novo Nordisk

The Motley Fool · 12 Aug 2026positive

A Motley Fool article compares Eli Lilly with Novo Nordisk, concluding that Eli Lilly has a stronger GLP-1 portfolio and pipeline than its competitor. It also notes that Eli Lilly has a better lineup outside the diabetes and weight-loss areas.

Why it matters — This indicates Eli Lilly's competitive edge over a major rival in the GLP-1 market, which is relevant to investors watching the company's pipeline and broader portfolio positioning.

Eli Lilly Beat Big and Raised Guidance. Wall Street Sees More Room to Run

24/7 Wall Street · 11 Aug 2026positive

Eli Lilly delivered a strong quarter with revenue growth, its fourth consecutive earnings-per-share beat, and a raise to its guidance. The company's performance led Wall Street to see further upside potential for the stock.

Why it matters — A Lilly watcher would care because the company's fourth straight EPS beat and raised guidance indicate strong recent performance and positive forward momentum.

3 Trending Stocks to Watch on Wall Street Today

Schaeffers Research · 11 Aug 2026neutral

The article highlights several trending stocks on Wall Street, noting that chipmaker Intel Corp made headlines with a $15 billion common stock offering to support AI consumer demand and is doubling down on that move. No specific mention is made of Eli Lilly & Co.

Why it matters — A LLY watcher would care only to note that this piece contains no news directly relevant to Eli Lilly & Co. today.

Eli Lilly takes weight-loss pill battle global with first Foundayo approval outside U.S.

CNBC · 11 Aug 2026positive

Eli Lilly's weight-loss pill Foundayo received approval in the U.K., becoming Europe's second GLP-1 weight-loss pill and its first approval outside the U.S. The drug will initially be available privately by prescription, with NHS access pending a cost-effectiveness review.

Why it matters — The U.K. approval marks Eli Lilly's first international expansion of Foundayo, extending its GLP-1 weight-loss business beyond the U.S. market.

Why Eli Lilly Topped the Market Today

The Motley Fool · 10 Aug 2026positive

Eli Lilly topped the market today following news that its drug, while not the first of its type sold in a country with a population of almost 60 million, will benefit from Lilly's considerable marketing power behind it.

Why it matters — LLY watchers would care because the drug's launch in a market of nearly 60 million people, backed by the company's marketing strength, could broaden its commercial reach.

FAQ

Frequently asked questions about LLY stock

What is the LLY stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Eli Lilly & Co. have a median 12-month price target of $1,344, with estimates ranging from $850 to $1,600. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LLY stock a buy right now?

Of the 28 analysts covering Eli Lilly & Co., 22 rate it a Buy, 4 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Eli Lilly & Co. 90 out of 100 across roughly 4,600 US stocks as at 10 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LLY?

As at 10 Aug 2026, Eli Lilly & Co. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will LLY stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +10.6% from the last close, and Ticker Nerd's factor model ranks Eli Lilly & Co. 90 out of 100 as at 10 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LLY stock forecast for 2030?

No analyst covering Eli Lilly & Co. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LLY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $850 to $1,600 over the next 12 months.

How has LLY stock performed over the past year?

Eli Lilly & Co. returned +92.6% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eli Lilly & Co. do?

Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing prescription medicines for human health. Headquartered in Indianapolis, Indiana, and founded in 1876, the company operates in therapeutic areas that include diabetes, obesity, oncology, immunology, neuroscience, and other specialty conditions.

What is the latest news on LLY?

The most recent item we track (The Motley Fool, 12 Aug 2026): "Better Buy: Eli Lilly vs. Novo Nordisk". A Motley Fool article compares Eli Lilly with Novo Nordisk, concluding that Eli Lilly has a stronger GLP-1 portfolio and pipeline than its competitor. It also notes that Eli Lilly has a better lineup outside the diabetes and weight-loss areas.

Company

About Eli Lilly & Co.

Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing prescription medicines for human health. Headquartered in Indianapolis, Indiana, and founded in 1876, the company operates in therapeutic areas that include diabetes, obesity, oncology, immunology, neuroscience, and other specialty conditions. Eli Lilly and Company’s portfolio features innovative treatments for metabolic diseases, cancer, autoimmune disorders, and neurological conditions, supported by a broad pipeline of biologics, small molecules, and next-generation therapies. The company conducts research and clinical development across multiple geographies and manufactures medicines through facilities in the United States, Puerto Rico, Europe, and Asia, distributing its products in around 90 countries. Eli Lilly and Company plays a significant role in the healthcare system by working with physicians, hospitals, payers, and governments to make its therapies available to patients worldwide, while maintaining a single core business segment centered on human pharmaceutical products.

CEO Mr. David A. Ricks · 50,000 employees · United States · https://www.lilly.com